Prenetics Global (NASDAQ:PRE) CEO Danny Sheng Wu Yeung Buys 17,181 Shares

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung bought 17,181 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the transaction, the chief executive officer directly owned 112,416 shares of the company’s stock, valued at $2,386,591.68. This represents a 18.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Thursday, August 20th, Danny Sheng Wu Yeung purchased 7,500 shares of Prenetics Global stock. The shares were purchased at an average price of $18.31 per share, with a total value of $137,325.00.

Prenetics Global Price Performance

NASDAQ:PRE opened at $21.82 on Tuesday. The company has a market cap of $368.19 million, a price-to-earnings ratio of -5.25 and a beta of 0.26. Prenetics Global Limited has a 1 year low of $7.18 and a 1 year high of $23.63. The stock’s 50 day simple moving average is $19.07 and its two-hundred day simple moving average is $18.90.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The firm had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. As a group, analysts anticipate that Prenetics Global Limited will post -1.86 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday. Benchmark lifted their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Prenetics Global presently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

Hedge Funds Weigh In On Prenetics Global

Several hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new stake in Prenetics Global in the third quarter worth about $65,000. UBS Group AG raised its holdings in shares of Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after buying an additional 39,733 shares during the period. Kingsview Wealth Management LLC bought a new stake in shares of Prenetics Global during the 4th quarter worth approximately $172,000. Goldman Sachs Group Inc. bought a new stake in shares of Prenetics Global during the 4th quarter worth approximately $665,000. Finally, T3 Companies LLC purchased a new position in Prenetics Global during the 4th quarter valued at $170,000. 25.01% of the stock is currently owned by institutional investors.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.